Financial Performance - Q3 2025 - Bio-Rad's Q3 2025 GAAP revenue was $653 million, with a gross margin of 52.6% and an operating margin of 10.0%[6] - The company's Q3 2025 GAAP net cash from operations was $121 million[6] - Bio-Rad's Q3 2025 non-GAAP revenue was also $653 million, with a gross margin of 53.5% and an operating margin of 11.8%[7] - The company's Q3 2025 non-GAAP free cash flow was $89 million[7] Segment and Geographic Revenue Mix - Q3 2025 - Clinical Diagnostics accounted for 60% of the company's revenue, while Life Science accounted for 40%[10] - Americas contributed 47% of the company's revenue, EMEA 34%, and APAC 19%[10] - Life Science Group revenue was $262 million[12, 13] - Clinical Diagnostics Group revenue was $391 million[14] Balance Sheet Highlights - September 30, 2025 - The company's cash and short-term investments totaled $1.419 billion[15] - Long-term debt stood at $1.201 billion[15] - Investment in Sartorius AG was $4.643 billion[15] Full-Year 2025 Outlook - The company maintains its full-year 2025 outlook for currency neutral revenue growth of 0.0% to +1.0%[16] - The company anticipates free cash flow between $310 million and $330 million[16]